San­doz's Hu­mi­ra biosim­i­lar nabs sig­nif­i­cant mar­ket share thanks to CVS part­ner­ship

The nine biosim­i­lars com­pet­ing with Ab­b­Vie’s megablock­buster Hu­mi­ra have tried every­thing from ex­act­ly im­i­tat­ing the lat­est ver­sion of brand-name Hu­mi­ra to tak­ing more than 80% off the list price. But where they failed be­fore, they may have found a new play­book in a part­ner­ship be­tween San­doz and CVS.

Last Au­gust, CVS cre­at­ed a sub­sidiary to work di­rect­ly with biosim­i­lar de­vel­op­ers, kick­ing off with a deal to sell San­doz’s Hu­mi­ra biosim­i­lar Hy­ri­moz. Ef­fec­tive­ly, the re­la­tion­ship be­tween the for­mer gener­ics arm of No­var­tis and one of the top three phar­ma­cy ben­e­fit man­agers en­abled Hy­ri­moz to skip ahead of Hu­mi­ra on its for­mu­la­ry and make the first dent in the brand name’s mar­ket share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER